Dr Reddy’s Labs launches osteoporosis drug in the US

Dr Reddy’s Laboratories Ltd said it launched raloxifene hydrochloride tablets –used to treat osteoporosis — in the US market.

Raloxifene hydrochloride tablets are a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets. A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use.

Raloxifene is used by women to prevent and treat bone loss (osteoporosis) after menopause. It slows down bone loss and helps to keep bones strong, making them less likely to break.

Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive breast cancer) after menopause.

The Evista brand and generic had US sales of approximately $265 million MAT for the most recent twelve months ending in September 2016 according to IMS Health.

Dr. Reddy’s Raloxifene tablets are available in 60 mg in bottle count sizes of 30, 100 and 1,000.

Evista is a registered trademark of Eli Lilly and Company.

The Food and Drug Administration (FDA or USFDA) is a federal agency of the United States Department of Health and Human Services, one of the United States federal executive departments. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and pharmaceutical drugs, vaccines, biopharmaceuticals etc.

Dr. Reddy’s Laboratories Ltd. is an India pharmaceutical company and offers products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

2016-11-11T15:10:29+00:00